Type 2 Inflammation Biomarkers

Panelists discuss how biomarkers of type 2 inflammation, such as blood eosinophils, serum IgE, and fractional exhaled nitric oxide, can aid in diagnosing and monitoring type 2 inflammatory diseases as well as in predicting treatment response.

EP: 1.Navigating the Challenges of Respiratory Diseases

EP: 2.The Impact of Atopic Dermatitis and Prurigo Nodularis

EP: 3.Linking Type 2 Inflammation to Asthma and COPD

EP: 4.Impact of Exacerbations in Type 2 Inflammatory Respiratory Diseases

EP: 5.Type 2 Inflammation: The Link Between AD and PN

EP: 6.Personalizing Treatment Selection

EP: 7.Navigating Treatment Challenges in Chronic Skin Conditions

EP: 8.Role of Biologics in Dermatological Care

EP: 9.Biomarkers as Tools in Management of Type 2 Inflammation

EP: 10.Strategies to Manage Type 2 Inflammation in Respiratory Diseases

EP: 11.Addressing Unmet Needs and Emerging Agents

EP: 12.Future Directions for Type 2 Inflammation Management

EP: 13.Type 2 Inflammatory Diseases and Impact on Quality of Life

Now Viewing

EP: 14.Type 2 Inflammation Biomarkers

EP: 15.How Type 2 Inflammation Influences Treatment Choices

EP: 16.Complications of Uncontrolled Disease and Management of Comorbidities

EP: 17.Patient Education and Emerging Therapies

EP: 18.Unmet Needs and Future Research

• What tests or biomarkers are used to determine if a patient’s disease may be caused by type 2 inflammation? How does this information aid your medication selection process?

Related Videos

Related Content

Advertisement

December 2nd 2024

CMS, HHS Finalize Mandatory Model to Boost Kidney Transplant Access, Equity

Brooke McCormick

The 6-year mandatory Increasing Organ Transplant Access Model aims to boost kidney transplants and address disparities by incentivizing hospitals, enhancing care coordination, and measuring transplant outcome performance.

October 29th 2024

Breaking the Cycle: The Importance of Early Intervention in Hidradenitis Suppurativa

Giuliana Grossi

Prompt care supports mental well-being, as hidradenitis suppurativa is often associated with depression and anxiety due to its physical and social challenges.

December 2nd 2024

Baseline Response Rates Inform Immunotherapy Sequencing in NSCLC

Maggie L. Shaw

Investigators were seeking clarification on optimal sequencing of the immune checkpoint inhibitor atezolizumab following treatment failure and disease progression after receipt of nivolumab and pembrolizumab.

July 18th 2024

Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.

November 29th 2024

sGFAP May Predict Progression Independent of Relapse in BCDT-Treated MS

AJMC Contributor

The findings show that increases in serum glial fibrillary acidic protein throughout B-cell depletion therapy are associated with disability worsening despite not relapsing—known as progression independent of relapse activity.

November 29th 2024

Authors Identify Monoclonal Antibody to Selectively Target CALR Mutations in MPNs

Mary Caffrey

A decade after the discovery of CALR, the results are the first for a possible therapy for CALR-mutated MPNs to reach the clinic.

Related Content

Advertisement

December 2nd 2024

CMS, HHS Finalize Mandatory Model to Boost Kidney Transplant Access, Equity

Brooke McCormick

The 6-year mandatory Increasing Organ Transplant Access Model aims to boost kidney transplants and address disparities by incentivizing hospitals, enhancing care coordination, and measuring transplant outcome performance.

October 29th 2024

Breaking the Cycle: The Importance of Early Intervention in Hidradenitis Suppurativa

Giuliana Grossi

Prompt care supports mental well-being, as hidradenitis suppurativa is often associated with depression and anxiety due to its physical and social challenges.

December 2nd 2024

Baseline Response Rates Inform Immunotherapy Sequencing in NSCLC

Maggie L. Shaw

Investigators were seeking clarification on optimal sequencing of the immune checkpoint inhibitor atezolizumab following treatment failure and disease progression after receipt of nivolumab and pembrolizumab.

July 18th 2024

Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.

November 29th 2024

sGFAP May Predict Progression Independent of Relapse in BCDT-Treated MS

AJMC Contributor

The findings show that increases in serum glial fibrillary acidic protein throughout B-cell depletion therapy are associated with disability worsening despite not relapsing—known as progression independent of relapse activity.

November 29th 2024

Authors Identify Monoclonal Antibody to Selectively Target CALR Mutations in MPNs

Mary Caffrey

A decade after the discovery of CALR, the results are the first for a possible therapy for CALR-mutated MPNs to reach the clinic.